Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713–25. https://doi.org/10.1056/NEJMra1102942.

Article  CAS  PubMed  Google Scholar 

Kaplan GG, Bernstein CN, Coward S, Bitton A, Murthy SK, Nguyen GC, et al. The impact of inflammatory bowel disease in Canada 2018: epidemiology. J Can Assoc Gastroenterol. 2019;2(Suppl. 1):S6-16. https://doi.org/10.1093/jcag/gwy054.

Article  PubMed  Google Scholar 

Claytor J, Kumar P, Ananthakrishnan AN, Colombel JF, Agrawal M, Ungaro RC. Mild Crohn’s disease: definition and management. Curr Gastroenterol Rep. 2023;25(3):45–51. https://doi.org/10.1007/s11894-023-00863-y.

Article  PubMed  Google Scholar 

Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F, On behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Treatment algorithms for Crohn’s disease. Digestion. 2020;101(Suppl 1):43–57. https://doi.org/10.1159/000506364.

Article  CAS  PubMed  Google Scholar 

Kohli A, Moss AC. Personalizing therapy selection in inflammatory bowel disease. Rev Expert Rev Clin Immunol. 2023;19(4):431–8. https://doi.org/10.1080/1744666X.2023.2185605.

Article  CAS  PubMed  Google Scholar 

Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des. 2014;20(7):1082–96. https://doi.org/10.2174/13816128113199990416.

Article  CAS  PubMed  Google Scholar 

Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5(1):2–3. https://doi.org/10.1016/S2468-1253(19)30358-9.

Article  PubMed  Google Scholar 

Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21:40.

Article  PubMed  Google Scholar 

Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [published erratum appears in Lancet. 2020 Oct;396(10256):e56]. Lancet. 2017;390(10114):2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0.

Huppertz-Hauss G, Høivik ML, Langholz E, Odes S, Småstuen M, Stockbrugger R, et al. Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis. Inflamm Bowel Dis. 2015;21(2):337–44. https://doi.org/10.1097/MIB.0000000000000272.

Article  PubMed  Google Scholar 

Thapwong P, Norton C, Rowland E, Farah N, Czuber-Dochan W. A systematic review of the impact of inflammatory bowel disease (IBD) on family members. Rev J Clin Nurs. 2023;32(9–10):2228–38. https://doi.org/10.1111/jocn.16446.

Article  Google Scholar 

Coward S, Benchimol EI, Bernstein CN, Avina-Zubieta A, Bitton A, Carroll MW, Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC), et al. Forecasting the incidence and prevalence of inflammatory bowel disease: a Canadian nationwide analysis. Am J Gastroenterol. 2024;119(8):1563–70. https://doi.org/10.14309/ajg.0000000000002687.

Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology. Lancet Gastroenterol Hepatol. 2023;8(5):P458-492. https://doi.org/10.1016/S2468-1253(23)00003-1.

Article  Google Scholar 

Panés J, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. Gastroenterology. 2022;162(7):1891–910.

Article  PubMed  Google Scholar 

Shivashankar R, et al. Incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857–63.

Article  PubMed  Google Scholar 

Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kupčinskas J, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5(5):454–64.

Article  PubMed  Google Scholar 

Kuenzig ME, Benchimol EI, Lee L, Targownik LE, Singh H, Kaplan GG, et al. The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol. 2019;2(Suppl 1):S17–33. https://doi.org/10.1093/jcag/gwy055.

Article  PubMed  Google Scholar 

Kuenzig ME, Coward S, Targownik LE, Murthy SK, Benchimol EI, Windsor JW, et al. The 2023 impact of inflammatory bowel disease in Canada: direct health system and medication costs. J Can Assoc Gastroenterol. 2023;6(Suppl 2):S23–34. https://doi.org/10.1093/jcag/gwad008.

Article  PubMed  PubMed Central  Google Scholar 

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, COIN Study Group and the Dutch Initiative on Crohn and Colitis, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014;63(1):72–9. https://doi.org/10.1136/gutjnl-2012-303376.

Lamb C, Kennedy N, Raines T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–106. https://doi.org/10.1136/gutjnl-2019-318484.

Article  PubMed  Google Scholar 

Bernstein CN, Eliakim A, Fedail S, et al. World Gastroenterology Organisation Global Guidelines. Inflammatory bowel disease: update August 2015. J Clin Gastroenterol. 2016;50:803–18. https://doi.org/10.1097/MCG.0000000000000660.

Article  PubMed  Google Scholar 

Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74. https://doi.org/10.1053/j.gastro.2009.12.035.

Article  PubMed  Google Scholar 

Panaccione R, Steinhart H, Bressler B, et al. Canadian Association of Gastroenterology clinical practice guideline for the management of luminal Crohn’s disease. J Can Assoc Gastroenterol. 2019;2:e1–34. https://doi.org/10.1093/jcag/gwz019.

Article  PubMed  Google Scholar 

Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–61.

Article  PubMed  Google Scholar 

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, GEMINI 1 Study Group, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. https://doi.org/10.1056/NEJMoa1215734.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, for the GEMINI 2 Study Group, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369:711–21. https://doi.org/10.1056/NEJMoa1215739

Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691–9.

Article  PubMed  Google Scholar 

Wilson MR, Zouraq IA, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017;9:641–52. https://doi.org/10.2147/CEOR.S135609.

Article  PubMed  PubMed Central  Google Scholar 

Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Ther Adv Gastroenterol. 2020;13:1756284820941179. https://doi.org/10.1177/1756284820941179.

Article  CAS  Google Scholar 

Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, et al. Cost Effectiveness of subcutaneous vedolizumab for maintenance treatment of ulcerative colitis in Canada. Pharmacoecon Open. 2022;6(4):519–37. https://doi.org/10.1007/s41669-022-00331-9.

Article  PubMed  PubMed Central  Google Scholar 

Zhou T, Sheng Y, Guan H. Cost-effectiveness of vedolizumab in the treatment of moderate-to-severe Crohn’s disease in China. Adv Ther. 2021;38(8):4233–45. https://doi.org/10.1007/s12325-021-01806-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol. 2016;3(1): e000093. https://doi.org/10.1136/bmjgast-2016-000093.

Article  PubMed  PubMed Central  Google Scholar 

Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, et al. Cost-effectiveness analysis of vedolizumab compared with other biologics in anti-TNF-naïve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics. 2020;38(1):69–84. https://doi.org/10.1007/s40273-019-00841-1.

Article  PubMed  Google Scholar 

Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A, et al. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ. 2021;24(1):279–90. https://doi.org/10.1080/13696998.2021.1881323.

Article  PubMed